Prognostic role of Ca125 response criteria and RECIST criteria: Analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer

✍ Scribed by Gabriella Ferrandina; Manuela Ludovisi; Giacomo Corrado; Vito Carone; Marco Petrillo; Giovanni Scambia

• Book ID: 113961530
• Publisher: Elsevier Science
• Year: 2008
• Tongue: English
• Weight: 516 KB
• Volume: 109
• Category: Article
• ISSN: 0090-8258
• DOI: 10.1016/j.ygyno.2008.01.039